Table 1.
Clinical features and baseline laboratory results of the cases
| Case 1 | Case 2 | Case 3 | Case 4 | |
|---|---|---|---|---|
| Age (years) | 56 | 48 | 27 | 36 |
| Gender | Male | Male | Female | Male |
| FPG (mg/dL) | 440 | 352 | 320 | 526 |
| HbA1c (%) | 8.2 | 10.1 | 12.5 | 12.6 |
| C-peptide (ng/mL) | 1.5 | 0.97 | 0.87 | 0.38 |
| GAD65Ab (IU/mL) | >2000 | 94 | 725 | 234 |
| Time from vaccination to symptom onset (weeks) | 2a | 8 | 3 | 3 |
FPG fasting plasma glucose (normal range: 70–100 mg/dL), HbA1c glycated hemoglobin (normal range: 4.0–5.6%). C-peptide normal range 1.1–4.4 ng/mL. GAD65Ab glutamate decarboxylase antibody-65 (normal range: 0–10 IU/mL)
aAfter administration of second dose